Premium
Synthesis of SHIP1‐Activating Analogs of the Sponge Meroterpenoid Pelorol
Author(s) -
Meimetis Labros G.,
Nodwell Matt,
Yang Lu,
Wang Xiaoxia,
Wu Joyce,
Harwig Curtis,
Stenton Grant R.,
Mackenzie Lloyd F.,
MacRury Thomas,
Patrick Brian O.,
MingLum Andrew,
Ong Christopher J.,
Krystal Gerald,
Mui Alice L. F.,
Andersen Raymond J.
Publication year - 2012
Publication title -
european journal of organic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 155
eISSN - 1099-0690
pISSN - 1434-193X
DOI - 10.1002/ejoc.201200631
Subject(s) - chemistry , biomimetic synthesis , stereochemistry , in vivo , total synthesis , combinatorial chemistry , microbiology and biotechnology , biology
Two biomimetic approaches have been used to synthesize analogs of the SHIP1‐activating sponge meroterpenoid pelorol ( 1 ). One approach started from the chiral pool plant natural product sclareolide, which has the same absolute configuration as pelorol. The second approach utilized an enantioselective polyene cyclization to efficiently access both absolute configurations of the pelorol meroterpenoid skeleton and to prepare A‐ring functionalized compounds. Selected analogs have been evaluated for water solubility and biological activity. It was found that the undesirable catechol and ester functionalities in 1 could be removed to give MN100 ( 3 ), without a decrease in SHIP1‐activating ability. A further refinement led to the resorcinol analog 18 , which is the most effective SHIP1‐activating pelorol analog made to date. The HCl salt of ent ‐ 28 , a C‐3 amino analog of 18 , is about 500,000‐fold more soluble in water than MN100 ( 3 ). (±)‐ 28·HCl activates SHIP1 in vitro, inhibits Akt phosphorylation in stimulated MOLT‐4 (SHIP+) cells, and is active in a dose‐dependent manner in a mouse model of inflammation when administered by oral gavage (ED 50 ≈ 0.1 mg/kg). Pelorol analogs ent ‐ 28 or (±)‐ 28 are promising chemical tools for further preclinical in vivo evaluation of the potential of SHIP1 activators as therapeutics for treating hematopoietic diseases involving aberrant activation of PI3K cell signaling.